Patent intelligence · US
US 10993967
Combinatorial cancer immunotherapy
Combinatorial cancer immunotherapy
Patent details — US 10993967
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 4, 2021
- Expiration
- Apr 29, 2041
- Applicant
- Senti Biosciences, Inc.
- Claims
- 31
- CPC classes
- A61K, A61K35/28, A61K38/20, A61K38/208
Quick answer
US 10993967 (Combinatorial cancer immunotherapy) is held by Senti Biosciences, Inc.. Status: granted. Granted May 4, 2021. Expires Apr 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Senti Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 31
- CPC classes
- A61K, A61K35/28, A61K38/20, A61K38/208, A61K48/005, A61P
More from Senti Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10993967?
US 10993967 (Combinatorial cancer immunotherapy) is held by Senti Biosciences, Inc.. Status: granted. Granted May 4, 2021. Expires Apr 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10993967?
Senti Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10993967 expire?
Our index shows an expiration date of Apr 29, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.